+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel

Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel

Inflammatory Bowel Diseases 21(2): 453-467

Epidemiological studies show that both the incidence of inflammatory bowel disease (IBD) and the proportion of people with obesity and/or obesity-associated metabolic syndrome increased markedly in developed countries during the past half century. Obesity is also associated with the development of more active IBD and requirement for hospitalization and with a decrease in the time span between diagnosis and surgery. Patients with IBD, especially Crohn's disease, present fat-wrapping or "creeping fat," which corresponds to ectopic adipose tissue extending from the mesenteric attachment and covering the majority of the small and large intestinal surface. Mesenteric adipose tissue in patients with IBD presents several morphological and functional alterations, e.g., it is more infiltrated with immune cells such as macrophages and T cells. All these lines of evidence clearly show an association between obesity, adipose tissue, and functional bowel disorders. In this review, we will show that the mesenteric adipose tissue and creeping fat are not innocent by standers but actively contribute to the intestinal and systemic inflammatory responses in patients with IBD. More specifically, we will review evidence showing that adipose tissue in IBD is associated with major alterations in the secretion of cytokines and adipokines involved in inflammatory process, in adipose tissue mesenchymal stem cells and adipogenesis, and in the interaction between adipose tissue and other intestinal components (immune, lymphatic, neuroendocrine, and intestinal epithelial systems). Collectively, these studies underline the importance of adipose tissue for the identification of novel therapeutic approaches for IBD.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054340271

Download citation: RISBibTeXText

PMID: 25248003

DOI: 10.1097/mib.0000000000000209

Related references

Su1905 Intestinal Adiponectin Receptor 1 (AdipoR1) Modulates Inflammation During Colitis: a Potential Link in Adipose Tissue-Intestinal Crosstalk During Inflammatory Bowel Disease. Gastroenterology 148(4): S-549, 2015

Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?. World Journal of Gastroenterology 13(15): 2145-2149, 2007

Is inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease. Gastroenterology 136(2): 400-403, 2009

Adipose tissue and inflammatory bowel disease pathogenesis. Inflammatory Bowel Diseases 18(8): 1550-1557, 2012

Adipose tissue profiles in inflammatory bowel disease. Proceedings of the Nutrition Society 52(1): 5A, 1993

Matrix metalloproteases role in bowel inflammation and inflammatory bowel disease: an up to date review. Inflammatory Bowel Diseases 20(12): 2379-2393, 2015

Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 33(1): 14-22, 2001

Faecal calprotection Validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. JPGN 31(Suppl. 2): S16, 2000

Faecal calprotectin Validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. Gut 46(11): A3, 2000

Epicardial Adipose Tissue Is Increased in Patients With Inflammatory Bowel Disease. Journal of Ultrasound in Medicine 35(9): 1859-1864, 2017

Adipokines and the role of visceral adipose tissue in inflammatory bowel disease. Annals of Gastroenterology 29(4): 424-438, 2016

Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome. Current Molecular Medicine 8(4): 258-273, 2008

Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 59(8): 1056-1065, 2010

Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. Current Molecular Medicine 8(4): 258-273, 2008

Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. Journal of Pediatric Surgery 39(2): 139-43; Discussion 139-43, 2004